OPKO Health stockholders elect all 11 director nominees and approve 2026 equity plan at annual meeting

1. All eleven nominees were elected to the Board of Directors with each director receiving votes as follows: Election of Directors For Against Abstain Broker Non-Votes Phillip Frost, M.D. 423,666,978 40,175,942 296,243 79,767,645 Jane H. Hsiao, Ph.D. 422,928,151 40,947,325 263,687 79,767,645 Elias A. Zerhouni, M.D. 420,402,573 42,561,617 1,174,973 79,767,645 Steven D. Rubin 409,356,877 54,519,219 263,067 79,767,645 Gary J. Nabel, M.D., Ph.D. 420,083,341 43,643,796 412,026 79,767,645 Prem A. Lachman, M.D. 428,600,587 35,002,548 536,028 79,767,645 Roger J. Medel, M.D. 428,125,427 35,411,814 601,922 79,767,645 John A. Paganelli 398,032,505 65,734,019 372,639 79,767,645 Richard C. Pfenniger, Jr. 424,416,857 39,352,175 370,131 79,767,645 Subbarao V. Uppaluri, Ph.D. 454,992,813 8,481,656 664,694 79,767,645 Alice Lin-Tsing Yu, M.D., Ph.D. 418,457,740 45,287,103 394,320 79,767,645

2. The stockholders voted to approve the Company’s 2026 Equity Incentive Plan as disclosed in the Company’s 2026 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows: For Against Abstain Broker Non-Votes 440,096,997 23,694,041 348,125 79,767,645

3. The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company’s 2026 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows: For Against Abstain Broker Non-Votes 446,238,170 17,487,326 413,667 79,767,645

4. The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes on this proposal were as follows: For Against Abstain 535,070,921 6,120,699 2,715,188 There were no broker non-votes for the proposal.